NEW ORLEANS, LA—A novel transcatheter intracardiac shunt device appears to provide sustained clinical benefit at 1 year in heart failure patients with preserved or only mildly reduced ejection ...

An FDA advisory panel unanimously agreed that Johnson & Johnson MedTech's V-Wave Ventura interatrial shunt's risks outweigh ...

Ventura's permanent interatrial shunt was designed to shunt blood from the left to right atrium to improve symptoms in ...

An FDA advisory panel gave a unanimous verdict for an interatrial shunt in heart failure: no way.

J&J is pursuing premarket approval for the heart shunt. Although advisory committees provide recommendations to the FDA, the ...

ATLANTA, GA — Despite promise for improving heart failure (HF) in pilot studies, an interatrial shunt (IAS) device did not meet the primary composite efficacy endpoint in a pivotal trial, a result ...

The first implantation of a new device called interatrial shunt device (IASD) is a success. This device is developed by Corvia Medical. The device is a non-surgical device that provides continuous ...

Please provide your email address to receive an email when new articles are posted on . Physiologic aqueous outflow pathways include the conventional outflow pathway and the uveoscleral outflow.

NEWARK, Del, Feb. 20, 2024 (GLOBE NEWSWIRE) -- According to Future Market Insights’ latest industry analysis, the Hydrocephalus Shunt Market size is estimated to be around US$ 546.09 million in 2024.

The US Food and Drug Administration (FDA) is warning healthcare providers about potential hazards from interactions between implanted programmable cerebrospinal fluid (CSF) shunts and hearing implants ...

New York, July 01, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Hydrocephalus Shunts (Neurology Devices) - Global Market Analysis ...